Who can use LYTGOBI(Futibatinib)?

Futibatinib (LYTGOBI) is a kinase inhibitor indicated for the treatment of adult patients with the following conditions: Unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with confirmed fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangements detected. This indication is approved under the accelerated approval program, based on the overall response rate (ORR) and duration of response (DoR). Further confirmation of clinical benefit through subsequent confirmatory clinical trials is required.